<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13310">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01944007</url>
  </required_header>
  <id_info>
    <org_study_id>CTST-5</org_study_id>
    <nct_id>NCT01944007</nct_id>
  </id_info>
  <brief_title>Evaluation of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers</brief_title>
  <official_title>Open-label Phase 1 Multiple Dose Escalation Trial to Assess the Safety, Tolerability, and Efficacy of Capsules Containing Cross-linked Polyelectrolyte (CLP) Given to Normal Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorbent Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorbent Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-escalation study to determine the effect of CLP in normal healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Net Sodium Balance</measure>
    <time_frame>Days 5 - 9</time_frame>
    <safety_issue>No</safety_issue>
    <description>Daily net sodium balance was calculated based on dietary and fluid intake, urinary and fecal output and emesis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Fecal Weight</measure>
    <time_frame>Days 1-9</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total fecal weight throughout 9-day treatment period, and mean fecal weights (daily avg. of Days 5-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Balance of Potassium, Magnesium, Calcium, and Phosphorous</measure>
    <time_frame>Days 5-9</time_frame>
    <safety_issue>No</safety_issue>
    <description>The net balance of cations was calculated based on dietary and fluid intake, urinary and fecal output, and emesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal content and concentration of sodium, potassium, magnesium, calcium, phosphorous, iron, zinc, and copper</measure>
    <time_frame>Days 5-9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine content and concentration of sodium, potassium, magnesium, calcium, and phosphorous</measure>
    <time_frame>Days 5-9</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of sodium, potassium, magnesium, calcium, and phosphorous</measure>
    <time_frame>Days 5-9</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Basic Science: Safety, Tolerability, Efficacy of CLP</condition>
  <arm_group>
    <arm_group_label>CLP 15 g Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLP 25 g Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLP 7.5 g Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CLP 15 g fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cross-Linked Polyelectrolyte (CLP)</intervention_name>
    <description>CLP was administered orally, in capsules, for 9 consecutive days.</description>
    <arm_group_label>CLP 15 g Fed</arm_group_label>
    <arm_group_label>CLP 25 g Fed</arm_group_label>
    <arm_group_label>CLP 7.5 g Fed</arm_group_label>
    <arm_group_label>CLP 15 g fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females between the ages of 18 and 70 years

          -  Body mass index (BMI) between 18 and 32 kg/m^2, inclusive

          -  Females could not be pregnant or breast feeding and had to be using birth control

        Exclusion Criteria:

          -  Positive drug screen for substances of abuse

          -  Positive results for HIV, hepatitis B, or hepatitis C

          -  Screening 12-lead ECG demonstrating QTc interval &gt;430 msec for males and &gt;450 msec
             for females, or any cardiac rhythm disorder considered by the Investigator to be
             clinically relevant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Blok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jasper Clinic, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jasper Clinic, Inc.</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 16, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLP</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
